Diagnosis, epidemiology, and management of hypertension in children

Pediatrics

Volumn 138, Issue 2, 2016, Pages

  Rao, Goutham ^a,b,c  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMILORIDE; AMLODIPINE; ATENOLOL; AZILSARTAN MEDOXOMIL; BENAZEPRIL; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; ENALAPRIL; FELODIPINE; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IRBESARTAN; ISRADIPINE; LABETALOL; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; PROPRANOLOL; QUINAPRIL; SPIRONOLACTONE; TRIAMTERENE; UNINDEXED DRUG; VALSARTAN; ANTIHYPERTENSIVE AGENT;

AGE DISTRIBUTION; ARTERIAL WALL THICKNESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GENDER BIAS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MICROALBUMINURIA; MORBIDITY; OBESITY; ONSET AGE; PATHOPHYSIOLOGY; PEDIATRICS; PHYSICAL ACTIVITY; POPULATION DISTRIBUTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SODIUM INTAKE; TREATMENT INDICATION; ADOLESCENT; CHILD; PRESCHOOL CHILD; UNITED STATES;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CHILD; CHILD, PRESCHOOL; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 84980491050     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-3616     Document Type: Review

References (69)

1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55(1):33-50
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913
3. Blumenthal S, Epps RP, Heavenrich R et al Report of the task force on blood pressure control in children. Pediatrics. 1977;59( suppl 2):I-II, 797-820
4. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298(8):874-879
5. Brady TM, Solomon BS, Neu AM, Siberry GK, Parekh RS. Patient-, provider-, and clinic-level predictors of unrecognized elevated blood pressure in children. Pediatrics. 2010;125(6). Available at: http://pediatrics. aappublications.org/content/125/6/e1286
6. Riley M, Dobson M, Sen A, Green L. Recognizing elevated BP in children and adolescents: how are we doing? J Fam Pract. 2013;62(6):294-299
7. Moyer VA; U.S. Preventive Services Task Force. Screening for primary hypertension in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(9):613-619
8. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520
9. Master AM, Dublin LI, Marks HH. The normal blood pressure range and its clinical implications. J Am Med Assoc. 1950;143(17):1464-1470
10. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(suppl 2):555-576
11. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(suppl 5): S213-S256
12. Lurbe E, Cifkova R, Cruickshank JK, et al; European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719-1742
13. Urbina E, Alpert B, Flynn J, et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension. 2008;52(3):433-451
14. Flynn JT, Urbina EM. Pediatric ambulatory blood pressure monitoring: indications and interpretations. J Clin Hypertens (Greenwich). 2012;14(6):372-382
15. Lubrano R, Paoli S, Spiga S et al Impact of ambulatory blood pressure monitoring on the diagnosis of hypertension in children. J Am Soc Hypertens. 2015;9(10): 780-784
16. Seeman T, Dostálek L, Gilík J. Control of hypertension in treated children and its association with target organ damage. Am J Hypertens. 2012;25(3):389-395
17. Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics. 2008;122(6):1177-1181
18. Tientcheu D, Ayers C, Das SR, et al. Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study. J Am Coll Cardiol. 2015;66(20):2159-2169
19. Flynn JT. Differentiation between primary and secondary hypertension in children using ambulatory blood pressure monitoring. Pediatrics. 2002;110(1 pt 1):89-93
20. Sorof JM, Cardwell G, Franco K, Portman RJ. Ambulatory blood pressure and left ventricular mass index in hypertensive children. Hypertension. 2002;39(4):903-908
21. Richey PA, Disessa TG, Hastings MC, Somes GW, Alpert BS, Jones DP. Ambulatory blood pressure and increased left ventricular mass in children at risk for hypertension. J Pediatr. 2008;152(3):343-348
22. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488-1496
23. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113(3 pt 1):475-482
24. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and prehypertension among adolescents. J Pediatr. 2007;150(6):640-644, 644.e1
25. Adrogué HE, Sinaiko AR. Prevalence of hypertension in junior high school-aged children: effect of new recommendations in the 1996 Updated Task Force Report. Am J Hypertens. 2001;14(5 pt 1):412-414
26. Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics. 2008;122(2):238-242
27. Zhang YX, Wang SR. Comparison of blood pressure levels among children and adolescents with different body mass index and waist circumference: study in a large sample in Shandong, China. Eur J Nutr. 2014;53(2): 627-634
28. Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics. 2013;131(2). Available at: http://pediatrics. aappublications.org/content/131/2/e415.
29. Kit BK, Kuklina E, Carroll MD, Ostchega Y, Freedman DS, Ogden CL. Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999-2012. JAMA Pediatr. 2015;169(3):272-279
30. US Census Bureau. 2010 Census. Available at: http://factfinder. census.gov/faces/tableservices/jsf/pages/productview. xhtml? src=bkmk. Accessed September 13, 2015.
31. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics. 1999;103(6 Pt 1):1175-1182
32. Salvadori M, Sontrop JM, Garg AX, et al. Elevated blood pressure in relation to overweight and obesity among children in a rural Canadian community. Pediatrics. 2008;122(4). Available at: http://pediatrics. aappublications.org/content/122/4/e821
33. Maldonado J, Pereira T, Fernandes R, Carvalho M. Blood pressure distribution of a sample of healthy Portuguese children and adolescents: the AVELEIRA registry. Rev Port Cardiol. 2009;28(11):1233-1244
34. Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension. 2013;62(2): 247-254
35. Kelishadi R, Mirmoghtadaee P, NajafiH, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with cardiometabolic risk factors. J Res Med Sci. 2015;20(3):294-307
36. Yang Q, Zhang Z, Kuklina EV, et al. Sodium intake and blood pressure among US children and adolescents. Pediatrics. 2012;130(4):611-619
37. McCrindle BW. Assessment and management of hypertension in children and adolescents. Nat Rev Cardiol. 2010;7(3):155-163
38. Bartosh SM, Aronson AJ. Childhood hypertension. An update on etiology, diagnosis, and treatment. Pediatr Clin North Am. 1999;46(2):235-252
39. Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. Am J Hypertens. 2015;28(1):73-80
40. Flynn J, Zhang Y, Solar-Yohay S, Shi V. Clinical and demographic characteristics of children with hypertension. Hypertension. 2012;60(4):1047-1054
41. Dwyer T, Sun C, Magnussen CG, et al. Cohort Profile: the international childhood cardiovascular cohort (i3C) consortium. Int J Epidemiol. 2013;42(1):86-96
42. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and metaregression analysis. Circulation. 2008;117(25):3171-3180
43. Daniels SR, Loggie JMH, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97(19):1907-1911
44. Hanevold C, Waller J, Daniels S, Portman R, Sorof J; International Pediatric Hypertension Association. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics. 2004;113(2):328-333
45. McNiece KL, Gupta-Malhotra M, Samuels J, et al; National High Blood Pressure Education Program Working Group. Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension. 2007;50(2):392-395
46. Brady TM, Fivush B, Flynn JT, Parekh R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr. 2008;152(1):73-78, 78.e1
47. Kavey REW. Left ventricular hypertrophy in hypertensive children and adolescents: predictors and prevalence. Curr Hypertens Rep. 2013;15(5):453-457
48. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459-467
49. Lamotte C, Iliescu C, Libersa C, Gottrand F. Increased intima-media thickness of the carotid artery in childhood: a systematic review of observational studies. Eur J Pediatr. 2011;170(6):719-729
50. Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation. 2013;128(3):217-224
51. Mitchell P, Cheung N, de Haseth K, et al. Blood pressure and retinal arteriolar narrowing in children. Hypertension. 2007;49(5):1156-1162
52. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16(9):1325-1333
53. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol. 2007;28(1):27-33
54. Assadi F. Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol. 2008;29(3):580-584
55. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20(6):791-797
56. Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev. 2014;2:CD008117
57. Takeda Pharmaceuticals. A comparative single-dose pharmacokinetic (pk) and safety study of azilsartan medoxomil in children with hypertension and in healthy adults. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01078376? term=azilsartan+hypert ension+children& rank=1. NLM identifier: NCT01078376. Accessed January 13, 2016
58. Novartis Pharmaceuticals. Safety and efficacy of aliskiren in pediatric hypertensive patients 6-17 years of age. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01150357? term=aliskiren+childre n& rank=2. NLM identifier: NCT01150357. Accessed January 13, 2016
59. Merck Sharp & Dohme Corporation. An extension study designed to assess effects of losartan on proteinuria in pediatric populations. Available at https://clinicaltrials.gov/ct2/show/NCT00568178? term=NCT00568178& rank=1. NLM identifier: NCT00568178. Accessed: January 11, 2016
60. Merck Sharp & Dohme Corporation. A study of losartan compared to losartan/HCTZ in pediatric patients with hypertension. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00447603? term=losartan+children +hypertension& rank=4. NLM identifier NCT00447603. Accessed January 13, 2016
61. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J; Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008;10(10): 743-750
62. Matteucci MC, Chinali M, Rinelli G, et al; ESCAPE Trial Group. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol. 2013;8(2):203-210
63. Seeman T, Gilík J, Vondrák K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20(9):990-996
64. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol. 2007;28(1):27-33
65. Litwin M, Niemirska A, Sladowska-Kozlowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol. 2010;25(12):2489-2499
66. National Quality Forum. Blood pressure screening by 13 years of age and blood pressure screening by 18 years of age. 2009. Available at: http://www.qualityforum.org/OPUS/IntentSubmission-List. aspx? opmenu=cfi& projectID=11& ContentID=28579
67. Lobach D, Sanders GD, Bright TJ et al Enabling health care decision making through clinical decision support and knowledge management (Evidence Report/Technology Assessments, No. 203. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Available at: http://www.ncbi. nlm. nih.gov/books/NBK97318
68. Brady TM, Neu AM, Miller ER III, Appel LJ, Siberry GK, Solomon BS. Real-time electronic medical record alerts increase high blood pressure recognition in children. Clin Pediatr (Phila). 2015;54(7): 667-675
69. The National Patient Centered Clinical Research Network. Clinical data research networks. Available at: www.pcornet.org/clinical-data-researchnetworks/. Accessed September 20, 2015